Cyanokit

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

hydroxocobalamin

Available from:

SERB SA

ATC code:

V03AB33

INN (International Name):

hydroxocobalamin

Therapeutic group:

Il-prodotti terapewtiċi l-oħra kollha

Therapeutic area:

Avvelenament

Therapeutic indications:

Trattament ta 'avvelenament magħruf jew suspettat ta' cyanide. Cyanokit għandu jingħata flimkien ma adegwati ta ' dekontaminazzjoni u miżuri ta'appoġġ.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2007-11-23

Patient Information leaflet

                                43
B. FULJETT TA’ TAGĦRIF
44
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
_ _
CYANOKIT 2.5 G TRAB GĦAL SOLUZZJONI GĦALL-INFUŻJONI
hydroxocobalamin
AQRA SEW DAN IL-FULJETT KOLLU QABEL TUŻA DIN IL-MEDIĊINA PERESS LI
FIH INFORMAZZJONI IMPORTANTI
GĦALIK.

Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.

Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.

Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Cyanokit u għalxiex jintuża
2.
X’għandek tkun taf qabel ma jintuża Cyanokit
3.
Kif jintuża Cyanokit
4.
Effetti sekondarji possibbli
5.
Kif jinħażen Cyanokit
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU CYANOKIT U GĦALXIEX JINTUŻA
Cyanokit fih is-sustanza attvia hydroxocobalamin.
Cyanokit hu antidotu għat-trattament ta’ avvelenament magħruf jew
suspettat b’cyanide fil-meded
kollha ta’ età.
Cyanokit għandu jingħata flimkien ma’ miżuri adegwati ta’
dekontaminazzjoni u sapport.
Cyanide hu kimika velenuża ħafna. L-avvelenament b’cyanide
jista’ jkun ikkawżat mill- espożizzjoni
għal duħħan minn nirien fid-dar jew industrijali, ġbid jew bligħ
bin-nifs ta’ cyanide, jew b’kuntatt ma’
cyanide fuq il-ġilda.
2.
X’GĦANDEK TKUN TAF QABEL MA JINTUŻA CYANOKIT
TWISSIJIET U PREKAWZJONIJIET
Għid lit-tabib tiegħek jew lil professjonist fil-qasam mediku ieħor
tat-trattament tas-saħħa

jekk inti allerġiku/a għal hydroxocobalamin jew vitamina B
12
. Dan irid ikun ikkunsidrat qabel
ma inti tkun trattat/a b’Cyanokit.

li inti kont trattat/a b’Cyanokit jekk ikollok bżonn ta’ dawn li
ġejjin:
-
kwalunkwe testijiet tad-demm jew tal-awrina. Cyanokit, jista’ jibdel
ir-riżultati ta’ dawn it-
testijiet.
-
evalwazzjoni ta’ ħruq. Cyanokit jista’ jinterferixxi
mal-evalwazzjoni għax jikkawża kulur
aħmar tal-ġilda.
-
emodijaliżi. Cy
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Cyanokit 2.5 g trab għal soluzzjoni għall-infużjoni
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull kunjett fih 2.5 g ta’ hydroxocobalamin.
Wara r-rikostituzzjoni b’100 mL ta’ diluwent, kull millilitru
tas-soluzzjoni rikostitwita jkun fih 25 mg
ta’ hydroxocobalamin.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Trab għal soluzzjoni għall-infużjoni.
Trab kristallin aħmar skur.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Trattament ta’ avvelenament magħruf jew suspettat b’cyanide
fil-meded kollha ta’ età.
Cyanokit għandu jingħata flimkien ma’ miżuri adegwati ta’
dekontaminazzjoni u sapport (ara
sezzjoni 4.4).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
_Doża inizjali _
_Adulti:_ Id-doża inizjali ta’ Cyanokit hi ta’ 5 g (2 x 100 mL).
_Popolazzjoni pedjatrika:_ Fi tfal żgħar sa adolexxenti (0 sa 18-il
sena), id-doża inizjali ta’ Cyanokit hi
ta’ 70 mg/kg piż tal-ġisem, u ma taqbiżx 5 g.
Piż tal-ġisem
f’kg
5
10
20
30
40
50
60
Doża inizjali
fi g
f’mL
0.35
14
0.70
28
1.40
56
2.10
84
2.80
112
3.50
140
4.20
168
_Doża sussegwenti_
Skond is-serjeta` ta’ l-avvelenament u r-rispons kliniku (ara
sezzjoni 4.4), tista’ tingħata t-tieni doża.
_Adulti:_ Id-doża sussegwenti ta’ Cyanokit hi ta’ 5 g (2 x 100
mL).
_Popolazzjoni pedjatrika: _Fi tfal żgħar sa adolexxenti (0 sa 18-il
sena), id-doża sussegwenti ta’
Cyanokit hi ta’ 70 mg/kg piż tal-ġisem, u ma taqbiżx 5 g.
Doża massima
_Adulti:_ Id-doża massima totali rakkomandata hi ta’ 10 g.
3
_Popolazzjoni pedjatrika:_ Fi tfal żgħar sa adolexxenti (0 sa 18-il
sena), id-doża massima totali
rakkomandata hi ta’ 140 mg/kg, u ma taqbiżx 10 g.
Indeboliment tal-kliewi u tal-fwied
Għalkemm is-sigurtà u l-effikaċja ta’ hydroxocobalamin ma kinux
studjati f’indebolimenti tal-kliewi u
tal-fwied, Cyanokit jingħata bħala terapija ta’ emerġenza
f’sitwazzj
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-01-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-01-2019
Public Assessment Report Public Assessment Report Bulgarian 23-07-2015
Patient Information leaflet Patient Information leaflet Spanish 18-01-2019
Public Assessment Report Public Assessment Report Spanish 23-07-2015
Patient Information leaflet Patient Information leaflet Czech 18-01-2019
Public Assessment Report Public Assessment Report Czech 23-07-2015
Patient Information leaflet Patient Information leaflet Danish 18-01-2019
Public Assessment Report Public Assessment Report Danish 23-07-2015
Patient Information leaflet Patient Information leaflet German 18-01-2019
Public Assessment Report Public Assessment Report German 23-07-2015
Patient Information leaflet Patient Information leaflet Estonian 18-01-2019
Public Assessment Report Public Assessment Report Estonian 23-07-2015
Patient Information leaflet Patient Information leaflet Greek 18-01-2019
Public Assessment Report Public Assessment Report Greek 23-07-2015
Patient Information leaflet Patient Information leaflet English 18-01-2019
Public Assessment Report Public Assessment Report English 23-07-2015
Patient Information leaflet Patient Information leaflet French 18-01-2019
Public Assessment Report Public Assessment Report French 23-07-2015
Patient Information leaflet Patient Information leaflet Italian 18-01-2019
Public Assessment Report Public Assessment Report Italian 23-07-2015
Patient Information leaflet Patient Information leaflet Latvian 18-01-2019
Public Assessment Report Public Assessment Report Latvian 23-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 18-01-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-01-2019
Public Assessment Report Public Assessment Report Lithuanian 23-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 18-01-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 18-01-2019
Public Assessment Report Public Assessment Report Hungarian 23-07-2015
Patient Information leaflet Patient Information leaflet Dutch 18-01-2019
Public Assessment Report Public Assessment Report Dutch 23-07-2015
Patient Information leaflet Patient Information leaflet Polish 18-01-2019
Public Assessment Report Public Assessment Report Polish 23-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 18-01-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 18-01-2019
Public Assessment Report Public Assessment Report Portuguese 23-07-2015
Patient Information leaflet Patient Information leaflet Romanian 18-01-2019
Public Assessment Report Public Assessment Report Romanian 23-07-2015
Patient Information leaflet Patient Information leaflet Slovak 18-01-2019
Public Assessment Report Public Assessment Report Slovak 23-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 18-01-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 18-01-2019
Public Assessment Report Public Assessment Report Slovenian 23-07-2015
Patient Information leaflet Patient Information leaflet Finnish 18-01-2019
Public Assessment Report Public Assessment Report Finnish 23-07-2015
Patient Information leaflet Patient Information leaflet Swedish 18-01-2019
Public Assessment Report Public Assessment Report Swedish 23-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 18-01-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 18-01-2019
Patient Information leaflet Patient Information leaflet Icelandic 18-01-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 18-01-2019
Patient Information leaflet Patient Information leaflet Croatian 18-01-2019
Public Assessment Report Public Assessment Report Croatian 23-07-2015

Search alerts related to this product

View documents history